GENO Genovis AB (publ.)
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisREX, a protease that digests proteins C-terminally of arginine residues. In addition, the company offers OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase; OpeRATOR, an O-glycan-specific protease; ImpaRATOR, an O-glycan-dependent protease; OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a ß-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; and GlycOCATCH, an affinity resin. Further, it provides GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a family of antibody products; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody, as well as SEQURNA RNase Inhibitor Thermostable. Additionally, the company offers antibodies, proteins, antigens, kits, and cell culture products; bioprocess and gene therapy services; and services, such as SmartEnzymes fragmentation and conjugation, antibody LC-MS analysis, and customized antibody services. It serves biotech and pharmaceutical, contract research, and contract manufacturing companies. The company was founded in 1999 and is headquartered in Kävlinge, Sweden.…
Industry Peers
BiotechnologyKey Statistics
About Genovis (STO: GENO)
›
Genovis (STO: GENO) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 43 employees.
The shares were at 23.40 SEK on 19 November 2026, up 14.1% over 52 weeks. Its 52-week range is 15.64 SEK to 24.55 SEK: the price is 4.7% below the high and 49.6% above the low.
At a market capitalisation of 1.58B SEK, it trades at 93.6 times trailing earnings and 49.8 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a premium of 179% for GENO.
Genovis reports return on equity of 8.7%, an operating margin of 16.6% and revenue up 33.9% year over year.
It holds more cash than debt, a net cash position of 92.59M SEK. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 34.00 SEK is 45.3% above the current price.